💰 Module 01 · Risk-Adjusted Valuation

rNPV Calculator & Scenario Modeling

Probability-of-success-weighted NPV with adjustable inputs across peak sales, PTRS by phase, discount rate, and time-to-launch. Monte Carlo simulation for value distribution.

🎛️ Valuation Inputs

Asset

Peak Annual Sales ($M)3,800

Years to Peak7

PTRS to Launch (%)62

Discount Rate (%)10.5

Patent Life (yr post-launch)12

COGS (%)18

Royalty Outflow (%)8

rNPV (Base)

$2.84B

risk-adjusted

Unadjusted NPV

$4.58B

100% PTRS

PoS-Weighted Peak

$2.36B

62% × $3.8B

Cumulative Cost

$1.42B

to launch

📊 Cash Flow Profile (Risk-Adjusted)

Annual probability-adjusted cash flows from current state through patent expiry.

🎲 Monte Carlo — rNPV Distribution

10,000 simulations across input uncertainty.

📉 Tornado — rNPV Sensitivity

⚡ Valuation Strategic Brief

ASC-301 rNPV of $2.84B base case with 80% confidence interval $1.6B - $4.2B. Monte Carlo P10/P50/P90 of $1.4B / $2.84B / $4.3B.

Largest drivers: Peak sales (±32% of rNPV swing), PTRS (±28%), and IRA price erosion in Year 6+ (±18%). Peak sales assumption is the most negotiable input in deal discussions.
Deal floor: At P25 ($2.1B), supports upfront ≤ $400M + back-end ≤ $1.2B for licensee-side economics. Above $400M upfront, deal becomes value-destructive in conservative scenario.
Asymmetry note: rNPV distribution is right-skewed (mean $2.94B vs median $2.84B). Earn-out structures or contingent value rights (CVR) capture this upside without overpaying upfront.

📚 Module 02 · Deal Comparables

Comparable Deals Database

Recent biopharma licensing and acquisition deals filtered by therapeutic area, stage, deal type, and structure. Benchmarking for upfront, milestone, and royalty terms.

Comparable Deals

42

last 36 months

Median Upfront

$285M

oncology Phase 3

Median Total BV

$1.84B

upfront + milestones

Median Royalty

12%

tiered

📋 Recent Comparable Deals (Oncology · Phase 2-3)

Year	Licensor → Licensee	Asset	Phase	Indication	Upfront	Milestones	Total BV	Royalty
2025	BeOne Med → Pfizer	BGB-A1217 (TIGIT)	Ph2	NSCLC, GC	$520M	$3.2B	$3.72B	15-22%
2025	Nuvation → Merck KGaA	Taletrectinib (ROS1)	Ph3	NSCLC	$680M	$1.84B	$2.52B	12-18%
2024	Arcus → AstraZeneca	Domvanalimab	Ph3	NSCLC, GI	$420M	$2.4B	$2.82B	15-25%
2024	Daiichi Sankyo / AZ	Datopotamab DXd	Ph3	NSCLC, BC	$1.0B	$5.0B	$6.0B	50/50 P&L
2024	Roivant → Pfizer	RVT-3101 (TL1A)	Ph2	IBD	$1.0B	$1.5B	$2.5B	Profit share
2024	Genmab → AbbVie	Epcoritamab	Ph3	DLBCL, FL	$750M	$3.15B	$3.9B	Profit share
2023	Mirati → BMS	Adagrasib (KRAS)	Approved	NSCLC, CRC	$4.8B	N/A (acq)	$4.8B	N/A
2023	Seagen → Pfizer	Whole company	Multi	Multi-onc	$43B	N/A (acq)	$43B	N/A
2023	Prometheus → Merck	PRA023 (TL1A)	Ph2	UC, CD	$10.8B	N/A (acq)	$10.8B	N/A
2023	ChemoCentryx → Amgen	Tavneos (ANCA)	Approved	Vasculitis	$3.7B	N/A (acq)	$3.7B	N/A
2023	HUTCHMED → Takeda	Fruquintinib	Ph3	CRC	$400M	$730M	$1.13B	15-30%
2022	SpringWorks/ Catalent	Mirdametinib (NF1)	Ph2	NF1-PN	$135M	$685M	$820M	10-15%

📊 Deal Value by Phase

💸 Upfront / Total BV Mix

⚡ Comparable Deal Strategic Brief

For an ASC-301-equivalent asset (Phase 3 NSCLC, TIGIT-class), the comparable benchmark is BeOne→Pfizer ($520M upfront, $3.72B BV) and Nuvation→Merck KGaA ($680M upfront, $2.52B BV).

Expected range: Upfront $450-700M, total biobucks $2.5-4B, tiered royalties 15-22%. Anchor at upper end if Phase 3 readout positive.
Structure trend: 4 of 12 recent comparables included profit-share (50/50 or asymmetric) replacing royalty. Profit-share suits high-conviction assets with shared commercial execution; consider for ASC-301 if licensee has competing oncology franchise.
Acquisition vs license: Mirati ($4.8B) and Prometheus ($10.8B) acquisitions demonstrate the premium for whole-company deals — typically 2-3× license total BV when synergies exist.

🔧 Module 03 · Deal Structuring

Deal Structure Simulator

Optimize upfront, milestones, royalty, and equity mix for value-maximizing and risk-balanced deal structures. Tradeoff analysis between cash-out and contingent value.

🎛️ Structure Inputs

Deal Position

Upfront ($M)550

Development Milestones ($M)800

Commercial Milestones ($M)1200

Royalty Tier 1 (%)12

Royalty Tier 2 (%)18

Equity Component (%)0

Total Deal Value

$2.55B

biobucks

NPV to Licensor

$1.42B

risk-adjusted

NPV to Licensee

$1.84B

accretive

Win-Win Zone

Yes

positive both sides

📊 Deal Cash Flow Distribution

🤝 Three Structure Scenarios

Scenario	Upfront	Dev MS	Comm MS	Royalty	Licensor NPV	Licensee NPV	Verdict
A: Heavy upfront	$1,000M	$500M	$800M	8%	$1.32B	$1.18B	Licensor-favored
B: Balanced	$550M	$800M	$1,200M	12/18%	$1.42B	$1.84B	Win-win
C: Heavy back-end	$250M	$1,000M	$2,000M	18/25%	$1.18B	$2.24B	Licensee-favored

⚡ Deal Structuring Strategic Brief

Balanced Scenario B ($550M upfront / $2B milestones / 12-18% tiered royalty) creates win-win zone with positive NPV for both parties. Three negotiation levers:

Upfront tradeoff: Each $100M of upfront cash erodes licensor NPV by ~$60M (cost of cash to licensor < royalty value) but reduces licensor PTRS exposure. Sweet spot is $500-600M upfront for Phase 3 oncology.
Royalty stepping: Tiered royalty (12% under $1B, 18% over $1B, 22% over $3B) creates upside alignment. Licensor captures more value if asset blockbusters.
Commercial milestones: Avoid sales-milestone "cliff" structures where small revenue shortfalls cost large milestones. Use sales-tier ladders ($1B, $2B, $3B) instead of point-in-time targets.

🎯 Module 04 · Decision Framework

In-Licensing Decision Matrix

Multi-criteria decision analysis for in-licensing opportunities. Scoring across strategic fit, scientific merit, commercial potential, and execution feasibility.

Assets Evaluated

12

in pipeline review

Recommend Pursue

3

tier 1 priorities

Recommend Pass

6

low strategic fit

Watch / Monitor

3

data readout pending

🏆 Asset Scoring Matrix

Asset	Indication	Phase	Strategic Fit	Science	Commercial	Execution	Composite	Verdict
ASC-301	NSCLC (TIGIT class)	Ph3	94	92	90	88	91	Pursue · Tier 1
IMD-118	UC (TL1A class)	Ph2	88	85	78	72	81	Pursue · Tier 1
RD-901	Pompe (ERT)	Ph3	82	88	68	75	78	Pursue · Tier 1
NEU-378	Major Depression (NMDA)	Ph2	68	72	82	68	72	Watch
CDM-188	HFpEF	Ph2	58	65	84	62	67	Watch
IMD-256	PsA (IL-23)	Ph3	72	75	68	70	71	Watch · pending data
RES-422	IPF (Wnt pathway)	Ph1b	42	68	62	48	55	Pass · early
VAC-552	RSV vaccine	Ph3	38	62	72	52	56	Pass · not in TA

⚡ Portfolio Decision Strategic Brief

Three Tier-1 priorities (composite ≥ 78) emerge from 12-asset review. Recommended portfolio strategy:

ASC-301 (composite 91): Pursue aggressively. Strongest strategic fit + Phase 3 + clear path to launch. Submit non-binding offer Q3 2026.
IMD-118 (composite 81): Pursue with option structure. Phase 2 risk warrants $150-250M upfront with $1.2-1.8B milestones tied to Phase 3 success.
RD-901 (composite 78): Rare disease specialty fit. Strategic value beyond NPV — establishes rare disease franchise for tax credits and pricing power.
Watch list: NEU-378 and IMD-256 await Phase 2 / Phase 3 readouts respectively. Decision points Q4 2026 and Q1 2027.
Capital allocation: Pursue all three Tier-1 if cumulative upfront under $1.2B; otherwise prioritize ASC-301 + RD-901 (uncorrelated TAs).

📊 Module 05 · Competitive Forecast

Asset Valuation & Competitive Forecast

Peak sales modeling under competitive scenarios, share-of-class projection, and patent-to-LOE revenue trajectory with biosimilar / generic erosion.

Class Peak (2030)

$28B

TIGIT class (NSCLC)

Asset Peak Share

14%

share-of-class

Peak Sales

$3.8B

year 7 global

LOE Erosion (Yr 1)

-65%

post-patent

📈 Lifetime Revenue Trajectory (15-year)

Lifecycle revenue from launch through LOE erosion, with competitive entry impacts.

⚔️ Competitive Landscape — TIGIT Class

Asset	Sponsor	Phase	Status	Peak Yr Est.
ASC-301	Internal	Ph3	Pivotal readout 2027	$3.8B
Tiragolumab	Roche	Ph3	Mixed Ph3 outcomes	$1.2B
Vibostolimab	Merck	Ph3	Combo w/ pembro	$2.4B
Domvanalimab	Arcus/AZ	Ph3	Ph3 enrollment	$3.1B
BGB-A1217	BeOne/Pfizer	Ph2	Promising Ph2 data	$2.0B

📊 Share-of-Class Forecast

⚡ Competitive Forecast Strategic Brief

TIGIT class is forecasted to reach $28B globally by 2030. ASC-301 captures 14% share ($3.8B peak) based on best-in-class efficacy in Phase 2 (OS HR 0.68 vs SoC) and projected first/second-to-market position in 1L NSCLC.

Competitive risk: Domvanalimab (Arcus/AZ) and Vibostolimab (Merck combo) are the two most threatening competitors. If both achieve broader 1L approval, ASC-301 share could compress to 8-10%.
Sequencing strategy: Aggressive 1L combination Phase 3 program is critical — head-to-head positioning vs SoC + checkpoint inhibitor is the highest-NPV indication expansion.
LOE planning: 12-year patent life implies LOE 2039. Begin life-cycle management strategy (2L development, fixed-dose combo, subcutaneous formulation) by Year 4 post-launch.